Utility of Multigene Assays in Management of Early Stage Breast Cancer

Numerous multigene-based assays have been developed to better prognosticate the risk of recurrence and death and predict benefit of therapy. Incorporating appropriate assays along with the traditional biomarkers in clinical decision-making still remains a challenge as all available tools have advantages and limitations that the clinicians should understand and explain to patients.

This information was originally presented at the NCCN 2019 Congress Series™: Breast Cancer with Updates from the 2018 San Antonio Breast Cancer Symposium (SABCS) held in Chicago, Illinois, on February 8, 2019.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with breast cancer.
 

Learning Objectives

Following this program, participants should be able to:

  • Describe the difference between breast cancer factors that are prognostic, predictive, or both. 
  • Compare multigene assays available for hormone receptor-positive, HER2-negative disease. 
  • Select appropriate multigene assays based on patient and tumor characteristics and individualize adjuvant systemic therapy recommendations.
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Genentech
  • Genomic Health, Inc.
  • Novartis
  • Pfizer
Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.64 ANCC contact hours
  • 0.75 Participation
Course opens: 
03/18/2019
Course expires: 
03/18/2020
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2019 Congress Series™: Breast Cancer

William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University 


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
MacroGenics, Inc.: Scientific Advisor
Roche Laboratories, Inc./Genentech, Inc.: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor

NCCN Staff Disclosures 
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Katherine Pierce (Employed by NCCN until 8/1/18)
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options 

Donald Harting, ELS, CHCP (Employed by NCCN until 12/3/18)
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Susan D. Darlow, PhD; Mary A. Dwyer, MS, CGC; Ellen Erkess; Deborah A. Freedman-Cass, PhD; Rashmi Kumar, PhD; Nicole R. McMillian, MS, CHES; Dorothy A. Shead, MS

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.64 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-023-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit.  Approval is valid until March 18, 2020. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.64 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: